首页> 外文期刊>Plastic and reconstructive surgery >Treatment of capsular contracture using complete implant coverage by acellular dermal matrix: A novel technique
【24h】

Treatment of capsular contracture using complete implant coverage by acellular dermal matrix: A novel technique

机译:使用脱细胞真皮基质完全覆盖种植体来治疗包膜挛缩:一种新技术

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Capsular contracture is a frequent complication of breast reconstruction that affects 2.8 to 15.9 percent of patients. Use of acellular dermal matrix has been reported for treatment of contracture, with a recurrence rate of 6.3 percent, but this was limited to partial implant coverage only. The authors describe a novel surgical technique using acellular dermal matrix to completely cover the implant anteriorly to treat and prevent capsular contracture. METHODS: Charts were reviewed to identify patients who had received implant insertion with complete acellular dermal matrix coverage performed by a single surgeon. Patient demographic information, history of irradiation or capsular contracture, prior treatment, and postoperative complications were recorded. RESULTS: Eleven patients (16 breasts) were identified. Mean age and body mass index were 52.3 ± 6.9 years and 23.6 ± 4.4 kg/m, respectively. Four patients (five breasts) had a history of capsular contracture requiring previous capsulectomy and implant exchange. Ten cases were for correction of new-onset grade III (n = 2) or IV (n = 8) capsular contracture and one was to prevent future capsular contracture. Mean acellular dermal matrix size was 229.8 ± 46.5 cm (range, 144 to 256 cm). Average follow-up was 9.2 months (range, 2.4 to 18.8 months). One patient (one breast) developed an infection requiring implant removal. No patients experienced recurrent capsular contracture. CONCLUSIONS: Capsular contracture may be treated successfully using complete acellular dermal matrix coverage. This technique may be a useful addition to therapies currently used to treat recalcitrant capsular contracture (early recurrence or refractory to standard therapy).
机译:背景:囊膜挛缩症是乳房再造的常见并发症,影响2.8%至15.9%的患者。已有报道使用脱细胞真皮基质治疗挛缩症,复发率达6.3%,但这仅限于部分植入物覆盖。作者介绍了一种使用脱细胞真皮基质完全覆盖种植体的新型外科手术技术,以治疗和预防囊膜挛缩。方法:对图表进行回顾,以鉴定接受植入物植入的患者,该植入物由单位外科医生进行完全脱细胞的真皮基质覆盖。记录患者的人口统计学信息,放射线或囊膜挛缩的病史,既往治疗以及术后并发症。结果:确定了11例患者(16个乳房)。平均年龄和体重指数分别为52.3±6.9岁和23.6±4.4 kg / m。四名患者(五个乳房)有囊膜挛缩病史,需要事先进行囊切开术和更换植入物。 10例用于矫正新发的III级(n = 2)或IV(n = 8)包膜挛缩,其中1例是为了预防将来的包膜挛缩。平均无细胞真皮基质尺寸为229.8±46.5 cm(范围为144至256 cm)。平均随访时间为9.2个月(范围2.4到18.8个月)。一名患者(一只乳房)发生感染,需要移除植入物。没有患者经历复发性囊膜挛缩。结论:完整的脱细胞真皮基质覆盖可以成功治疗囊膜挛缩。该技术可能是当前用于治疗顽固性囊膜挛缩症(早期复发或标准疗法难治)的有用疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号